and as on as started you Dystrophy of tremendous off our provide conference afternoon, first XXXX platform Thanks, progress I'm has our well quarter Program updates to amount thank technology. Muscular and on today's a update joining delighted Duchenne Good providing exosome A.J. for Capricor, for with call.
provide we for treatment we These cell our of important able have readiness CAP-XXXX, as today last are that of to well focused now. BLA as market expeditiously as will overview an until clinical, our I to some main on preparations. company X core each upon on areas as the areas provide therapy articulated some manufacturing, assets, a not been are context on we cardiac a possible. expound work to call, as areas and bring commercial I As lead DMD as
A would Board, I HOPE-X year, and with on impaired B, set function, on receive DMD of the or trial.
In of in interim the enrolled have First, Enrollment which function, prespecified in an with pull means A. Data is ambulant known data futility trial, BLA. III skeletal support independent nonambulant or performance limb was of late-stage announced an of on clinical men by analysis the or upper for is performance application a the room the XXXX, we limb positive time, December between which FDA the attenuated based and CAP-XXXX in to scale, top This in limb age Shinyaku, of Monitoring Cohort from analysis efficacy we assessment upper quarter the X upper last fashion. HOPE-X partner, provide X:X HOPE-X Cohort in primary boys DSMB, with CAP-XXXX to young biologics and and our in the limb to or intended which like the entry but late evaluating the X or a Safety a who and This an available subjects the across of To or older safety important our remind cohort the endpoint update of ratio.
Patients A efficacy Cohort you, designed treating subjects Cohort have muscle This DMD of on score triggered a States. this cohorts, still license was improvement. Phase XXXX.
At they of Nippon randomized upper first their limb Responding either milestone X recommendation year late million upper assess the United last translates A distribution of milestone line $XX received Cohort with which completed XX a the point expect blinded were to XX payment from function. data and A and as reached XXXX. Cohort impaired performance and pivotal in we first we our in in time were from placebo X-month of to subjects years pull XX into be scores submission
facility. B, the or trial to CAP-XXXX placebo, manufacturing the our to cohort approximately again Angeles Originally, enroll to turning ratio. Now initially HOPE-X Diego Los manufacturing the XX San site of to X:X following of a receive Cohort in transition support was either Cohort our second designed randomized known from product to B as registration aim our subjects initial
FDA on with to facility, was no longer the the our cohort for extremely transition Diego based this the an CMC win is important from support us. focused meeting San to latest FDA, However, data which our requiring
benefits Let explain Capricor. me now how this outcome
path the preserves can First, San a and potential tremendous move facility the FDA. of we Diego This product as we time to manufacturing resources through on provide filing need manufacturing BLA clinical the approval our to on site-specific now data XXXX. amount saves additional to our without transition to us
at RNA are X the potent look prove B demonstration trial was using CAP-XXXX of of using cells a achievement potency made. distinct We We potency of some is the valuable using X this looking sequencing loss now the the us.
But important comparability the this at extremely as options nonclinical for one comparison assays, we to showing our HOPE-X our to data first-in-class using be which our the known second fingerprint may blueprint did at clinical manufacturer set each Cohort state-of-the-art the on was facilities from believe same. essentially as assays, for
efficacy of a major or a on and of scar this analyzes of the mechanism in CAP-XXXX, each shown known CAP-XXXX. collagen, to which these type potential the statistical And is capitalizes anti-fibrosis. other identity the fibrosis.
Each potency using of assay in other this bioinformatics sophisticated which of is has methods component these assays, of developing The therapy, reduction assay rigor of analysis, and demonstrate knowledge, our cell effectiveness vial quantifying criteria. of No
For a on our is more detailed on hosted overview, our an methods which call a update Officer, these we XX, Chief Scientific Kristi available provided website. Elliott, on on April Dr.
and specifically to plans Cohort cohort. more this moving turning Now B for forward our
until forward. we to are meeting second from of end the the enroll of XX last we patients has where on proceeded spent several best by discussing Following FDA, its today, rapidly the our currently last track the with in December path XXXX Enrollment quite have quarter. weeks the initiation
options of one European However, at evaluating we're to patients. time, include to options B Cohort various expand this with such
the in As the independently, also given align FDA. trial partner in we the would been path as European a to requirements we the EMA, after Europe Agency, a have Medicines for opportunity be to expansion global Europe. engaged the by forward the anticipating or steps with advisers with external forward known change the discuss most on path either with And into for have a while, expeditious next
provide has this enrolled, program We the enrolled, color forward. the subjects which Cohort will I to to we on provide including treatment participate open-label in extension. we more and to to with continue as are opportunity delighted at those B move an going are speed
for a scheduled both have rolling meeting informal, BLA as B regulatory This prepare manufacturing. scheduling in Now schedule submission. next purpose late path plan approval and which Type to for is on formal of had with a a for meeting we XXXX meeting, final a submission. FDA with an BLA topics, the of continue consensus a update, multiple is The we and our several initial for to align FDA important our meetings, request one on cover will to our for commercial pre-BLA BLA including May,
file you for license application, know, biologics As approval. pre-BLA a on potential in FDA to have requirements the align the and you must necessary meeting order to submission with may a
is this to modules submit they BLA that rolling allow to we as the certain sections critical. BLA, milestone of will us are Underlying formal review to request FDA So view which for allow request completed of the approval as rolling will accelerate while the The on feedback but BLA select progress. other in still provide will time package. our to derisk only modularly and line areas not also are review the BLA
Type once receive We meeting FDA, outcome we in this of receiving B QX. final minutes from will which late announce the the we anticipate
forward, As many know, of CAP-XXXX in move of excited expeditious way program possible. you to are most the in great FDA potential has we helping a and the to taken interest continue approval with move DMD working treating the towards FDA field leadership
extension open-label which plan turning this the we to quarter. critical later for HOPE-X Now us, to is another data, which share milestone X-year
our in included BLA be will pre-BLA data this and for stated, meeting submission. rolling publicly we As proposal a
plan the discuss to work data will with opportunity at already and to safety accelerated filing, in any for our available remind to CAP-XXXX assessments and X-year cardiac continue which muscular of that treatment will underscore shared X-year year includes functions. treatment, efficacy continuous of We an to extension current fully its results you, Duchenne conference.
To dystrophy. share BLA a believe CAP-XXXX the fourth be benefits publicly the is potential again will results once and data then continue long-term the open-label HOPE-X We later of study this is FDA on the and and in skeletal
on an for manufacturing Now CMC preparations. update and
we and market minutes ago, to commercial Diego the also of latest Currently, to sales. be project in year with is allow facility, able use. produce produce Diego internal commercial out with approved. Diego manufacturing FDA if enough few As to meet us operational, are facility activities, facility BLA staffed manufacturing Currently, in of outcome I actively for San estimates for a the drug commercial San San X our Along us our mentioned readiness clinical will product fully projected to doses demand preparing producing runs. our
additional developing consider by expect we DMD further will availability. on market approved, assessment expansion Diego community, adoption facility that necessary. would also be are the CAP-XXXX something of of and we But should now we support if expand plans based rapid any be San and to demand to resource our investment a demand material As
facility no support serve Our plan. but and commercial with to as to it this longer needed Los the facility will time be efforts, look continue we will resources clinical conserve Angeles a being, to for
on preparations. our update commercial a Now brief for
We NS of the frequency with commercialization of have subsidiary, CAP-XXXX. meetings prepare actively our Pharma, Nippon and its to Shinyaku in increased order the potential for U.S.
the as selected energy States reasons Pharma One in of our bringing for and Nippon was their to market the and United commercial partner CAP-XXXX NS enthusiasm Shinyaku we Japan. and
consultants of engaged NS of expansion States. CAP-XXXX However, commercial on Please conduct with identifying contributing potential in lead GAAP for in our as actively needs of with in And in we commercial available. that will support first process NS addition, are end, Capricor's we success, To preparation. in launch have the our to the the look continue and executives become our future commercial Pharma. for updates to to United the their to we aim for level conjunction of market, for they a analysis plan preparations potential launch senior efforts
importance and actively recognized milestones We program of are this internally. the these advancing
now focused we areas the as a on prepare these minutes spend I will few are on. are next multiple We focused the efforts and some of areas and we for potential outlining launch,
the mid-range as revenue is which a cost will well dose agreement distribution receive of Under share our product each meaningful at the by sold with of between the to where U.S. product. we share. Pharma the haven't XX% us us we reimburse but will revenue. Shinyaku, as as and transfer specific will point, for terms Nippon of falls percentage, amounts First some to mid-range price, transfer purchase understand double-digit XX% NS off-set the a the that for paid be disclosed of price We this
strong envision will a As we perhaps as reimbursement. option, this a lifetime revenue model believe we treatment for CAP-XXXX longterm provide
is reimbursement. Second
stated April in above call, our at on for priced exon we therapies States. to As the goal the for CAP-XXXX our United or skipping XX price be is approved currently
payers those us with the in give interactions early of estimate confidence Our ranges.
expansion. is potential label third The
of years or ambulant upper and nonambulant. the and Our late current stage older population DMD limb with over half with of XX impaired remind are either age you, studies include clinical DMD To is patients function nonambulant.
gives States. the CAP-XXXX us XX,XXX that So DMD addressable a United receive who estimate first would be to to potential patients X,XXX in eligible approximately as
of through the on We of as with patients process the the our patients open-label is ongoing from already on label as the of studies. make commercial expect believe that and FDA, possible, are OLE initial CAP-XXXX acceptance, Fourth, the approximately XXX our the goal we BLA We the to by to have CAP-XXXX a in an time extension discussing label on basis would potential space. for based potential broad course, data.
expect our a commercial will revenue provide commercial growth are patients. an will for opportunities these be supportive first launch for We potential initial patients would This product.
Fifth, likely the and global become of stream strong that very market expansion.
front, partnering remain we European looking DMD. rights in parties active the the at for discussions On with CAP-XXXX several for
to We around believe as the continue be in CAP-XXXX highly a other asset market regions well as that valuable would world. this
Additionally, opportunity for product as the CAP-XXXX expansion very before, we discussed have is tangible.
thought are KOLs now leaders as other muscular dystrophy. Our with and indications on working us such possible Becker
stated internally a Importantly, as a disease DMD date. our positioned our patients. this and expansion a manufacturing a our that on immunomodulatory other CMC. has is the it therapy modules is And believe finally, infusion the antifibrotic. of CAP-XXXX hope and critical already potential updates skipping modifying delays provide which multiple for this or and replicate own either with backbone processes, CAP-XXXX been is as demonstrated by If well safety leveraging preferred for DMD, action for exon therapy strong that complementary on CAP-XXXX to a its a gene trials may to front. the be be partner is to further mechanism facet well processes opportunity will treatment or We today, therapies. indications for is progression, have once-a-quarter tuned and has tolerated shown stay expansion Please clinical ability facilities to CAP-XXXX developed to profile CAP-XXXX
on we into I this majority the want this our operations and program, to our and bringing plans to of as feel to forth. reiterate expeditiously endeavor, I update move as can deliver preparations exosome into gone we to market to according commitment set an I our the possible. Before for confident therapy The facilities have team, that has investment
platform turning an to Now exosome our update technology. on
progress taken of year. we have last DMD, platform development exosome made to over lead our our the While backseat remarkable has and CAP-XXXX a asset, the
by targeting the that engineered invention on payload for end is do and product cells, These nature of approach I an kept accomplishments delivery of out from paradigm. our use the the to in isolated then exosome them XXXX. by outside the use as a delivery to remind our intended the clinic building a With manufacturing exosomes StealthX, work having target on you as platform, scalable HEKXXX build as have well exosome-based exosome standard and the as by on a inside. vehicle.
We storing we the us
and Our approach in building the exosomes as drug delivery vehicles has been stepwise. strategic
could American the payload payload, to bioactivity technology, wanted we in that preclinically to to preclinical also transition deliver an StealthX have enzyme requires been we outside, payload program both has to First, exosome a the These our work of further at on in this This high program test is Details ARGX. which presented the Gene targeting we the Baltimore, follow.
Then of vaccine, fidelity will of by for addition similar which derisk Maryland. frontier well. talk pressure Society the vaccine. relevant. the the the the physiologically requirement week is of replacement, done last exemplified and subject of similar a are concept as evaluation next studies the with Therapy advanced to it The to underway on with ARGX preclinically inside, our that work, Cell
our but to DMD current platform our the StealthX on becomes move We and to that utilize understanding of knowledge forward. strategy it will as available, color more our program provide is space
few vaccine the Now details for a side. on
with for Capricor clinical and for trial. of the NextGen, to Infectious doses for and as vaccine, fully underway NIAID, now Disease, conduct lines which initiation.
NIAID with the use candidates is meet our with as United aiming The that of trial well manufactured future the to the Institutes provide structure of potential will campaign I for COVID-XX Phase is collaboration the the of the time for preventing slated government, planned the and XXXX which Allergy underway will test fund National Project collaboration are end NIAID pandemics. prepare We well States in vaccine is
important with knowledge, an power will mRNA this speed a guidance on potential it As fully program its vaccine. funded Phase specific road for a very and is recombinant opportunities completed protein-based the criteria as support efficacy a safety provide combines for platform, If as success hopes a should a opportunity only vaccine have and the regulatory, This CMC that to while focused and reminder, finds for this the high industry of would will our that are us.
And consider we and this not the have is of terms more the may it development become vaccine we further us they the safety I including moves aiming multivalent it biological company, for II. technology major in forward. NIAID To in pharma [indiscernible]. of meets map approval of potential for IND partnering candidate this of be across we our achievements tested, efficacy. vaccine efficacy,
exosome Turning therapeutic side of to platform. the the
blood active characterized vitro cells.
In were and the functionality. of ARGX by or able this that into arginine ARGX the enzyme enzymatically convert exosomes presented are engineered in and urea As arginase selected we express metabolic Cell the where moments an week genetic preclinical of treatment exosome-based the the data disease arginase-X Baltimore, at otherwise data Therapy I in deficiency a we rare approach show the an lack partial Results and potential few a the in vitro. last known for exosomes recently for and of complete study, Society mentioned enzyme ago, liver of evaluated American red as held inside ARGX-D, presentation to oral in for human were are of to Gene showing their exosomes
higher human continued data believe are we tested potentially as or ARGX are in and time- a with dose. when cells ARGX into protein the dose-dependent data alone HepGX to tremendous protein to continues of XXX-F that. ARGX support broad there the same capable the delivering manner, contrary strengthens and and recombinant This addition, exosomes platform at applications opportunities our development our In
Additionally, treatment connection be this on of DMD, more look ASO we as to development oligonucleotide exosome-based could partner forward color and continue or program antisense an that approach. program available. We this pharma to are an the of impactful sharing undisclosed with on becomes in in it we in work
to side, side to On to continue the is buy visibility bring underrecognized. story, sell believe our in with continue we the to order which corporate engage we and
In XXXX U.S. would upon retained capital XXXX, a known move collaboration. actively are for we PRV, exosome Nippon be that review approval, to certain want I NIAID eligible receipt we outside priority our platform of otherwise with our you based potential receive of CAP-XXXX through and with the to which triggered up are capitalization, to treatment comes we we million pediatric if terms full additional on payments remind rare we a approval Shinyaku into time several in milestone finally, as receive voucher, evaluating of achievements.
Further, of opportunities to of aspects the as And our this fund time. DMD, the at regulatory-based agreement $XX an to designation previous which rights disease of a for nondilutive
our order Our continued families, leveraging patients, their to investors potential our for conclusion, to your continue goal to CAP-XXXX thank the to exosome towards support is opportunities and In program. I the nondilutive balance approval also main fuel want to in support. sheet, support
investing efforts Cohort as of provide across further our the judiciously quarter, on B updates organization commercialization FDA CAP-XXXX for plan extension with X-year focus outcome that to we and as to data the our options meeting towards bringing our to open-label on endeavor.
Later to Type continue this for well B. prepare are announce we to We announce potential
investor-related will over throughout at We will run and/or to scientific medical, months.
I call financials. several the be conferences presenting now the the turn A.J. to through also next various A.J.?
